Guardant Health announced that it has been informed it will receive national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare, or MHLW, effective July 24 for its Guardant360 CDx liquid biopsy test for comprehensive genomic profiling, or CGP, for patients with advanced or metastatic solid tumor cancers. This announcement follows the regulatory approval of the Guardant360 CDx test by the MHLW in March 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH: